Johnson & Johnson (NYSE:JNJ) Shares Purchased by Quintet Private Bank Europe S.A.

Quintet Private Bank Europe S.A. boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 15.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 42,127 shares of the company’s stock after acquiring an additional 5,606 shares during the quarter. Quintet Private Bank Europe S.A.’s holdings in Johnson & Johnson were worth $6,827,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in JNJ. China Universal Asset Management Co. Ltd. acquired a new stake in Johnson & Johnson in the 1st quarter valued at $765,000. Shariaportfolio Inc. grew its stake in Johnson & Johnson by 2.3% in the first quarter. Shariaportfolio Inc. now owns 14,655 shares of the company’s stock valued at $2,318,000 after acquiring an additional 325 shares during the period. Prosperity Consulting Group LLC boosted its position in shares of Johnson & Johnson by 9.3% during the first quarter. Prosperity Consulting Group LLC now owns 11,255 shares of the company’s stock worth $1,780,000 after buying an additional 957 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Johnson & Johnson by 11.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 563,628 shares of the company’s stock worth $86,265,000 after acquiring an additional 55,653 shares in the last quarter. Finally, Centric Wealth Management raised its stake in Johnson & Johnson by 25.3% in the first quarter. Centric Wealth Management now owns 3,592 shares of the company’s stock valued at $519,000 after buying an additional 725 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $158.24 on Tuesday. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The business’s 50 day simple moving average is $163.18 and its 200 day simple moving average is $155.68. The company has a market cap of $380.98 billion, a price-to-earnings ratio of 22.90, a PEG ratio of 2.84 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.66 earnings per share. Sell-side analysts forecast that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.13%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the sale, the vice president now owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on JNJ. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. The Goldman Sachs Group lowered their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. Royal Bank of Canada lifted their price objective on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Citigroup raised their target price on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Finally, Wells Fargo & Company lifted their price target on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $175.93.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.